Equities Analysts Offer Predictions for BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of BioCryst Pharmaceuticals in a research report issued on Monday, June 30th. Cantor Fitzgerald analyst S. Seedhouse now expects that the biotechnology company will post earnings per share of $0.06 for the year, down from their previous estimate of $0.09. Cantor Fitzgerald has a “Overweight” rating and a $20.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Cantor Fitzgerald also issued estimates for BioCryst Pharmaceuticals’ FY2026 earnings at $0.27 EPS.

BCRX has been the subject of several other reports. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Needham & Company LLC reissued a “buy” rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. Bank of America lifted their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday. Royal Bank Of Canada reissued an “outperform” rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday. Finally, JPMorgan Chase & Co. raised their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, May 6th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.70.

BioCryst Pharmaceuticals Stock Up 0.4%

Shares of BioCryst Pharmaceuticals stock opened at $9.00 on Tuesday. The company’s fifty day simple moving average is $10.01 and its two-hundred day simple moving average is $8.57. BioCryst Pharmaceuticals has a 12-month low of $6.02 and a 12-month high of $11.31. The firm has a market cap of $1.88 billion, a PE ratio of -34.62, a price-to-earnings-growth ratio of 2.32 and a beta of 1.04.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in BCRX. Millennium Management LLC lifted its position in shares of BioCryst Pharmaceuticals by 382.6% in the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock worth $28,597,000 after purchasing an additional 3,022,769 shares during the period. Vanguard Group Inc. lifted its holdings in BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after buying an additional 1,583,826 shares during the period. Eversept Partners LP boosted its position in BioCryst Pharmaceuticals by 269.9% during the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock valued at $14,892,000 after acquiring an additional 1,444,907 shares in the last quarter. Nuveen LLC bought a new stake in BioCryst Pharmaceuticals during the first quarter valued at about $10,677,000. Finally, Jupiter Asset Management Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 82.4% in the 1st quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company’s stock valued at $16,117,000 after buying an additional 971,040 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.